Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CTSC | P53634 | 10/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15084097 | 0.89 | CTSC (0.55) | GPR119CTSCCTSKKCNH2 | |
| SCHEMBL15084018 | 0.89 | CTSC (0.55) | GPR119CTSCCTSKKCNH2 | |
| SCHEMBL15081643 | 0.87 | CTSC (0.46) | GPR119CTSCCTSKKDM1A | |
| SCHEMBL15084085 | 0.83 | CTSC (0.47) | CTSCCTSKKCNH2 | |
| SCHEMBL15083997 | 0.83 | CTSS (0.41) | CTSKCTSS | |
| SCHEMBL15084021 | 0.82 | GPR119 (0.44) | GPR119 | |
| SCHEMBL14822357 | 0.81 | CACNA1B (0.39) | — | |
| SCHEMBL15083924 | 0.81 | MCL1 (0.39) | CTSC | |
| SCHEMBL15083921 | 0.80 | CACNA1B (0.38) | CTSC | |
| SCHEMBL15084019 | 0.80 | CACNA1B (0.38) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | CTSS, CTSB, CTSG | GPR119 2654/4885CTSC 9/4885CTSK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.